Shield Therapeutics (LSE:STX) Receivables Turnover : 0.72 (As of Jun. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Shield Therapeutics's Revenue for the six months ended in Jun. 2023 was £4.33 Mil. Shield Therapeutics's average Accounts Receivable for the six months ended in Jun. 2023 was £6.04 Mil. Hence, Shield Therapeutics's Receivables Turnover for the six months ended in Jun. 2023 was 0.72.

Shield Therapeutics Receivables Turnover Historical Data

The historical data trend for Shield Therapeutics's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shield Therapeutics Receivables Turnover Chart

Shield Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Receivables Turnover

Get a 7-Day Free Trial

77.40

2.81

47.43

2.94

2.46

Shield Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Receivables Turnover	Get a 7-Day Free Trial													0.43	0.74	1.00	0.51	0.72

Competitive Comparison of Shield Therapeutics's Receivables Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shield Therapeutics's Receivables Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Shield Therapeutics's Receivables Turnover falls into.

Shield Therapeutics Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Shield Therapeutics's Receivables Turnover for the fiscal year that ended in Dec. 2022 is calculated as

	Receivables Turnover (A: Dec. 2022 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2022 )	/ (	(Accounts Receivable (A: Dec. 2021 )	+	Accounts Receivable (A: Dec. 2022 ))	/	count )
=	4.467	/ (	(0.816	+	2.809)	/	2 )
=	4.467	/	1.8125
=	2.46

Shield Therapeutics's Receivables Turnover for the quarter that ended in Jun. 2023 is calculated as

	Receivables Turnover (Q: Jun. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Jun. 2023 )	/ (	(Accounts Receivable (Q: Dec. 2022 )	+	Accounts Receivable (Q: Jun. 2023 ))	/	count )
=	4.334	/ (	(2.809	+	9.262)	/	2 )
=	4.334	/	6.0355
=	0.72

Shield Therapeutics (LSE:STX) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Shield Therapeutics Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Shield Therapeutics (LSE:STX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

SHIEF:USA 1JS:Germany

Address

Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF

Website

https://www.shieldtherapeutics.com

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.